The year in charts

Financing led by Novo Holdings with significant support from world-class group of existing and new investors. Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the continued advancement of the company’s differentiated precision immunology pipeline.

The Innosuisse Innovation Council is currently looking for qualified experts to assist in reviewing funding applications, supporting innovation projects and implementing various innovation promotion activities. The task of these experts is to evaluate and make recommendations for the approval or rejection of funding applications for innovation projects.

ORYL Photonics introduces the ORYL F1, a novel automated laser-based platform for the measurement of solubility and aggregation of drug molecules in the Life Science industry. This is a significant achievement for the fast-growing Swiss company and for the solubility and aggregation community. The laboratory instrument enables researchers to make faster decisions and gain a deeper understanding of